基于设计锚蛋白重复蛋白介导的肽核酸预靶向:一项原理验证研究
本研究以靶向人表皮生长因子受体2(HER2)的设计锚蛋白重复蛋白(DARPin)G3为模型,通过分选酶A介导的连接将肽核酸(PNA)偶联至DARPin,构建预靶向系统。在小鼠HER2阳性SKOV-3和HER2阴性Ramos异种移植瘤中评估,预靶向使肿瘤摄取较直接靶向提高8倍,同时显著降低肾脏(约9倍)、肝脏(约370倍)和脾脏(6.5倍)的摄取。
要点
- 分选酶A介导偶联可构建基于PNA的DARPin G3预靶向系统。
- 预靶向使肿瘤摄取较直接靶向提高8倍。
- 预靶向使肾脏摄取降低约9倍、肝脏约370倍、脾脏6.5倍。
核心结论
- 分选酶A介导的偶联使得针对DARPin G3的PNA预靶向系统得以开发,将这一方法拓展至另一类工程支架蛋白。
研究设计与样本
- 原理验证研究,以靶向HER2的DARPin G3为模型,通过分选酶A介导连接将PNA偶联至DARPin G3的C端。
- G3-HP1用125I标记,含DOTA螯合剂的互补PNA二级探针HP2用177Lu标记。
- 体外研究在表达HER2的细胞系中进行,体内研究在携带HER2阳性SKOV-3和HER2阴性Ramos异种移植瘤的小鼠中进行。
主要发现
- [125I]I-G3-HP1以皮摩尔亲和力特异性结合表达HER2的细胞。
- [177Lu]Lu-HP2以亚纳摩尔亲和力、HER2特异性和PNA依赖性地结合经G3-HP1预处理的细胞。
- 预靶向使肿瘤摄取较[177Lu]Lu-DOTA-G3直接靶向提高8倍。
- 预靶向使肾脏摄取降低约9倍、肝脏降低约370倍、脾脏降低6.5倍。
- 基于Affibody分子和基于DARPin的预靶向中,[177Lu]Lu-HP2的生物分布和肿瘤摄取高度相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Designed ankyrin repeat proteins (DARPins) are a class of engineered scaffold proteins (ESPs) with a molecular weight of approximately 15 kDa and a picomolar affinity for tumor antigen targets. Proof-of-concept studies have demonstrated the potential of DARPin radioimmunodiagnostics in humans. However, a high accumulation of activity in the kidneys limits their use in conventional radionuclide therapy. A peptide nucleic acid (PNA)-based pretargeted approach was successfully applied to Affibody molecules, another class of ESP. We hypothesized that this method could also enable the controlled conversion of DARPins into pretargeting probes. In this proof-of-principle study, we tested this hypothesis using the human epidermal growth factor receptor type 2 (HER2)-targeting DARPin G3 as a model. Methods: We performed site-specific coupling of PNA to the DARPin using sortase A-mediated ligation. The DARPin G3 was modified at the C-terminus with a sortase A recognition sequence. A GGG-modified hybridization probe (HP1) containing a 15-base PNA sequence was attached to G3 using sortase A, creating the primary agent G3-HP1. To evaluate cell binding specificity and biodistribution, G3-HP1 was labeled with 125I. The complementary PNA-based secondary probe HP2 containing the DOTA chelator was labeled with 177Lu. In vitro studies were performed in HER2-expressing cell lines. Biodistribution and in vivo targeting and pretargeting specificity were evaluated in mice with HER2-positive SKOV-3 and HER2-negative Ramos xenografts. In vivo pretargeting of [177Lu]Lu-HP2 using G3-HP1 was head-to-head compared with Affibody molecule-mediated pretargeting using ZHER2:342-HP1 and with direct targeting using [177Lu]Lu-DOTA-G3. Results: [125I]I-G3-HP1 demonstrated specific binding to HER2-expressing cells with picomolar affinity. [177Lu]Lu-HP2 showed HER2-specific and PNA-dependent binding to G3-HP1-pretreated cells with subnanomolar affinity. Biodistribution studies confirmed HER2-specific tumor uptake of [125I]I-G3-HP1. The uptake of [177Lu]Lu-HP2 in xenografts was HER2-dependent and PNA-mediated in the case of G3-HP1 preinjection. The pretargeting approach increased the tumor uptake 8-fold compared with direct targeting using [177Lu]Lu-DOTA-G3. Pretargeting substantially decreased the uptake in the kidneys (∼9-fold), liver (∼370-fold), and spleen (6.5-fold). The biodistribution and the tumor uptake of [177Lu]Lu-HP2 were strikingly similar in the cases of Affibody- and DARPin-based pretargeting. Conclusion: Sortase A-mediated coupling enables the development of a PNA-based pretargeting system for DARPin G3, expanding the application of this approach to another class of ESPs.
引用
- Oroujeni M, Westerlund K, Papalanis E, et al. Designed Ankyrin Repeat Protein-Mediated Peptide Nucleic Acid-Based Pretargeting: A Proof-of-Principle Study. J Nucl Med. 2025. PMID: 40374553. doi:10.2967/jnumed.125.269533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。